TY - JOUR
T1 - Phase II study of 5′-deoxy-5-fluorouridine (doxifluridine) in advanced malignant melanoma
AU - Alberto, P.
AU - Rozencweig, M.
AU - Clavel, M.
AU - Siegenthaler, P.
AU - Cavalli, F.
AU - Gundersen, S.
AU - Bruntsch, U.
AU - Renard, J.
AU - Pinedo, H.
PY - 1986/1
Y1 - 1986/1
N2 - Forty-two patients with malignant melanoma were treated with doxifluridine, 4000 mg/m2 daily ×5, repeated every 3 weeks. The daily dose was reduced to 3000 mg/m2 in patients who had experienced severe myelosuppression with prior chemotherapy. A total of 35 patients were evaluable for response, and 25 of these received two or more courses. Two responses were observed. Toxicity mainly took the form of nausea, vomiting, stomatitis, dizziness, ataxia, and fatigue. Mild leukopenia was frequent (43%). Nadir counts 9/l leukocytes or 50×109/l platelets were seen in 7% and 2% of the courses respectively. Doxifluridine has no useful activity against malignant melanoma.
AB - Forty-two patients with malignant melanoma were treated with doxifluridine, 4000 mg/m2 daily ×5, repeated every 3 weeks. The daily dose was reduced to 3000 mg/m2 in patients who had experienced severe myelosuppression with prior chemotherapy. A total of 35 patients were evaluable for response, and 25 of these received two or more courses. Two responses were observed. Toxicity mainly took the form of nausea, vomiting, stomatitis, dizziness, ataxia, and fatigue. Mild leukopenia was frequent (43%). Nadir counts 9/l leukocytes or 50×109/l platelets were seen in 7% and 2% of the courses respectively. Doxifluridine has no useful activity against malignant melanoma.
UR - http://www.scopus.com/inward/record.url?scp=0022645414&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022645414&partnerID=8YFLogxK
U2 - 10.1007/BF00255292
DO - 10.1007/BF00255292
M3 - Article
C2 - 2933177
AN - SCOPUS:0022645414
SN - 0344-5704
VL - 16
SP - 78
EP - 79
JO - Cancer Chemotherapy and Pharmacology
JF - Cancer Chemotherapy and Pharmacology
IS - 1
ER -